Robert B. Ford Leads Abbott to Strong Q4 2025 Performance, Sets Stage for Accelerated Growth in 2026

Abbott reported solid fourth-quarter and full-year 2025 results, underscoring continued momentum across its diversified healthcare portfolio and positioning the company for faster growth in 2026, according to Chairman and CEO Robert B. Ford.

For the fourth quarter ended December 31, 2025, Abbott posted reported sales growth of 4.4%, with organic sales up 3.0%, or 3.8% excluding COVID-19 testing-related sales. GAAP diluted earnings per share (EPS) were $1.01, while adjusted diluted EPS reached $1.50, reflecting a 12% year-over-year increase. Medical Devices emerged as the primary growth engine, delivering double-digit organic growth driven by strong performance in Electrophysiology, Heart Failure, Rhythm Management, and Diabetes Care.

Full-year 2025 sales totaled $44.3 billion, representing reported growth of 5.7% and organic growth of 5.5%, or 6.7% when excluding COVID-19 testing-related sales. Full-year GAAP diluted EPS were $3.72, while adjusted diluted EPS rose 10% to $5.15. Established Pharmaceuticals continued to perform strongly, particularly in key emerging markets such as India, Latin America, and the Middle East, while Diagnostics results reflected the ongoing normalization of COVID-19 testing demand.

Abbott also made notable strategic and regulatory progress during the quarter. In November, the company announced an agreement to acquire Exact Sciences, a move expected to expand Abbott’s presence in the fast-growing cancer diagnostics market, with the transaction anticipated to close in the second quarter of 2026. In Medical Devices, Abbott strengthened its electrophysiology leadership with U.S. FDA approval of the Volt™ Pulsed Field Ablation System and CE Mark approval for the TactiFlex™ Duo Ablation Catheter.

Looking ahead, Abbott projects full-year 2026 organic sales growth of 6.5% to 7.5% and adjusted diluted EPS in the range of $5.55 to $5.80, representing approximately 10% growth at the midpoint.

“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,” said Robert B. Ford, Chairman and Chief Executive Officer of Abbott. “We’re well positioned for accelerating growth in 2026.”

The results reinforce Abbott’s strategy of balancing near-term performance with long-term investments in innovation, market expansion, and transformative acquisitions under the leadership of Robert B. Ford.

Read More